[ad_1]
Schwab Charles Investment Management Inc. acquired a new stake in Amyris Inc. (NASDAQ: AMRS) during the second quarter, according to its most recent disclosure with the SEC. 45.600 shares of the biotechnology company's stock, valued at approximately $ 292,000. Schwab Charles Investment Management Inc. owned about 0.09% of Amyris as its most recent filing with the SEC.
Several other large investors have also bought and sold shares of AMRS. Dynamic Technology Private Lab Ltd. acquired a new position in Amyris during the first quarter worth $ 110,000. Rhumbline Advisers purchased a new stake in shares of Amyris in the second quarter at about $ 147,000. Element Capital Management LLC was acquired in Amyris in the first quarter at $ 227,000. Barclays PLC raised its holdings in shares of Amyris by 30,067.8% in the first quarter. Barclays PLC now owns 44,950 shares of the biotechnology company's stock value at $ 300,000 after purchasing an additional 44,801 shares during the last quarter. Finally, BlackRock Inc. has raised its holdings in shares of Amyris by 139.2% in the first quarter. BlackRock Inc. now owns 53,414 shares of the biotechnology company's stock value at $ 358,000 after purchasing an additional 31,083 shares during the last quarter. 24.06% of the stock is currently owned by institutional investors.
Several brokerages have recently commented on AMRS. Zacks Investment Research downgraded shares of Amyris from a "hold" rating to a "sell" rating in a report on Tuesday, October 9th. B. Riley set a $ 10.00 amyris and gave the company a "buy" rating in a research report on Wednesday, October 3rd. HC Wainwright set a $ 15.00 Amyris and gave the company a "buy" rating in a research report on Friday, September 28th. BidaskClub upgraded shares of Amyris from a "hold" rating to a "buy" rating in a research report on Wednesday, August 15th. Finally, ValuEngine upgraded shares of Amyris from a "buy" rating to a "strong-buy" rating in a research report on Thursday, August 2nd. Two investment badysts have a rating, one has badigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. The stock currently has an average rating of "Hold" and an average price target of $ 7.63.
In other Amyris news, insider John Melo sold 5,195 shares of Amyris in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $ 7.50, for a total transaction of $ 38,962.50. Following the transaction, the insider now directly owns 743,713 shares of the company's stock, valued at $ 5,577,847.50. The transaction was disclosed to the Securities and Exchange Commission, which is available at this hyperlink. Also, Director Frank Kung sold 3,924,884 shares of Amyris in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $ 6.22, for a total transaction of $ 24,412,778.48. Following the transaction, the director now directly owns 4,266 shares in the company, valued at $ 26,534.52. The disclosure for this sale can be found here. Insiders sold 8,807,465 shares of company stock worth $ 54,789,082 over the last ninety days. 21.80% of the stock is currently owned by insiders.
Shares of AMRS stock traded down $ 1.76 during trading hours on Wednesday, reaching $ 4.14. The stock had a trading volume of 6,544,007 shares, compared to its average volume of 808,336. Amyris Inc has a 12 month low of $ 2.93 and a 12 month high of $ 9.28. The firm has a market capitalization of $ 408.28 million, a P / E ratio of -1.36 and a beta of 0.27.
Amyris (NASDAQ: AMRS) last released its quarterly earnings on Tuesday, November 13th. The biotechnology company reported ($ 1.13) EPS for the quarter, missing badysts' consensus estimates of ($ 0.17) by ($ 0.96). The firm had revenue of $ 14.90 million for the quarter, compared to the consensus estimate of $ 46.72 million. The company's revenue for the quarter was down 38.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($ 0.81) EPS. Analysts anticipate that Amyris Inc. will post -1.43 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article is reported by Fairfield Current and is the property of Fairfield Current. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.fairfieldcurrent.com/2018/11/14/schwab-charles-investment-management-inc-buys-shares-of-45600-amyris-inc-amrs. html.
Amyris Profile
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Featured Article: Moving Average (MA)
Receive News & Ratings for Amyris Daily – enter your email address below to receive a daily summary of the latest news and badysts' ratings for Amyris and related companies MarketBeat.com's FREE daily email newsletter.
Source link
